Sanofi acquired Tidal Therapeutics, a privately held biotechnology company on Friday for an upfront payment of $160 million. The company will pay another …
Regeneron Pharmaceuticals Inc (NASDAQ:REGN) and Sanofi SA (ADR) (NYSE:SNY) announced that, in a new pooled analysis of heterozygous familial hypercholesterolemia (HeFH) patients included in …
Ligand Pharmaceuticals Inc. (NASDAQ:LGND) announces it has entered into a global license and supply agreement with Sanofi SA (ADR) (NYSE:SNY) to utilize Captisol in …
In a research report released Tuesday, Canaccord analyst John Newman reiterated a Buy rating on Regeneron Pharmaceuticals Inc (NASDAQ:REGN) with a price target of …
Regeneron Pharmaceuticals Inc (NASDAQ:REGN) and Sanofi SA (ADR)(NYSE:SNY) have entered into a new global collaboration to discover, develop and commercialize new antibody cancer treatments …
Regeneron Pharmaceuticals Inc (NASDAQ:REGN) and Sanofi SA (ADR) (NYSE:SNY) announced that the European Medicine Agency’s (EMA’s) Committee for Medicinal Products for Human Use (CHMP) …
Regeneron Pharmaceuticals Inc (NASDAQ:REGN) and Sanofi SA (ADR) (NYSE:SNY) announced that the Phase 3 ODYSSEY JAPAN trial of the investigational therapy Praluent® (alirocumab) Injection …